Stocks and Investing
Stocks and Investing
Mon, October 31, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Kelsey Goodwin Initiated (TSVT) at Strong Buy and Held Target at $30 on, Oct 31st, 2022
Kelsey Goodwin of Guggenheim, Initiated "2seventy bio, Inc." (TSVT) at Strong Buy and Held Target at $30 on, Oct 31st, 2022.
Kelsey has made no other calls on TSVT in the last 4 months.
There is 1 other peer that has a rating on TSVT. Out of the 1 peers that are also analyzing TSVT, 0 agree with Kelsey's Rating of Hold.
This is the rating of the analyst that currently disagrees with Kelsey
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $27 on, Monday, August 15th, 2022
Contributing Sources